Oxybutynin Deemed Effective Treatment for Hyperhidrosis

This article originally appeared here.
Share this content:
Oxybutynin Deemed Effective Treatment for Hyperhidrosis
Oxybutynin Deemed Effective Treatment for Hyperhidrosis

(HealthDay News) -- Low-dose oxybutynin is an effective treatment for hyperhidrosis, according to a study published online June 26 in the British Journal of Dermatology.

Martine Schollhammer, M.D., from University Hospital in Brest, France, and colleagues examined the effectiveness and tolerance of low-dose oxybutynin for hyperhidrosis in a randomized placebo-controlled trial. Participants included 62 patients with localized or generalized hyperhidrosis (83 percent generalized). Oxybutynin was started at 2.5 mg per day and increased to 7.5 mg per day.

The researchers found that for improving the Hyperhidrosis Disease Severity Scale (HDSS), oxybutynin was superior to placebo, with improvement of at least one point on the HDSS for 60 percent of oxybutynin-treated patients versus 27 percent of placebo-treated patients. The mean improvement in quality of life, as measured by the Dermatology Life Quality Index, was significantly better for oxybutynin versus placebo treatment (6.9 versus 2.3). Dry mouth was the most frequent side effect, which was seen in 43 and 11 percent of those in the oxybutynin and placebo arms, respectively.

"Treatment with low-dose oxybutynin is effective in reducing symptoms of hyperhidrosis in generalized or localized forms," the authors write.

One author disclosed financial ties to Pfizer.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

Rising Fatal Drug Overdoses Linked to Years of Life Lost

Rising Fatal Drug Overdoses Linked to Years of ...

Growth in fatal overdoses linked to increased mortality, years of life lost for non-Hispanic whites

Atherosclerotic CVD Mortality Higher in South Asians in the U.S.

Atherosclerotic CVD Mortality Higher in South Asians in ...

Most of the increased risk can be attributed to increased prevalence of known risk factors

Global Variation in Personal Health Care Access and Quality

Global Variation in Personal Health Care Access and ...

Highest performance in Iceland, lowest in Central African Republic, with variation in rate of progress